Risk for thromboembolism and arteriosclerosis in women;Thromboembolie- und arterioskleroserisiko bei frauen

Zeitschrift fur Kardiologie

Volumn 91, Issue 7, 2002, Pages 523-535

  Nikol, Sigrid ^a   Middendorf, Katharina ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Arterial thromboembolism; Atherosclerosis; Estrogen; Hormone replacement therapy; Myocardial infarction; Venous thromboembolism

Indexed keywords

ESTROGEN; NITRIC OXIDE;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; LOWEST INCOME GROUP; ORAL CONTRACEPTION; REVIEW; RISK FACTOR; SEX DIFFERENCE; SMOKING; THROMBOEMBOLISM; THROMBOPHILIA; ADULT; AGE; AGED; ARTERIOSCLEROSIS; FEMALE; HEART INFARCTION; MIDDLE AGED; RISK;

ADULT; AGE FACTORS; AGED; ARTERIOSCLEROSIS; ENGLISH ABSTRACT; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN; MIDDLE AGE; MYOCARDIAL INFARCTION; RISK; THROMBOEMBOLISM; HUMANS; MIDDLE AGED;

EID: 0035986668     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-002-0807-1     Document Type: Review

References (64)

1. Initiation of hormone replacement therapy after acute myocardial infarction is asscociated with more cardiac events during follow-up
2. Gender and age bias in triage decisions
3. Acute myocardial infarction in women: Contribution of treatment variables to adverse outcome
4. Age as a risk factor for myocardial infarction in Leiden mutation carriers
5. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
6. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction
7. Interaction of coagulation defects and cardiovascular risk factors - Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A
8. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the studies of left ventricular dysfunction trials
9. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance
10. Differences between women and men in survival after myocardial infarction. Biology or methodology?
11. Clinical characteristics and follow-up of patients with chest pain and normal coronary arteries
12. Heart disease in women
13. Postmenopausal hormones and heart disease
14. Rechnung mit unbekannten: Gemeinsame stellungnahme der fachgesellschaften zu dem beitrag von klaus koch im Deutschen ärzteblatt 18 August
15. Prospective study of exogenous hormones and risk of pulmonary embolism in women
16. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study
17. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events
18. Factor V Leiden - An unselfish gene?
19. Effective risk stratification using exercise myocardial perfusion SPECT in women: Gender-related differences in prognostic nuclear testing
20. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute
21. Clinical pharmacology of selective estrogen receptor modulators
22. 17beta-estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats
23. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
24. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - Results of the randomized, double-blind, placebo-controlled etsrogen in venous thromboembolism trial (EVTET)
25. Myocardial infarction associated with homozygous resistance to activated protein C
26. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
27. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males
28. Gender differences in acute coronary events
29. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease
30. Analyse der xuweisungsdiagnosen bei patienten mit unauffälligem koronarangiogramm
31. Rechnung mit unbekannten: Nach einer aktuellen epidemiologischen berechnung ist die hormonersatztherapie bei frauen mit einem hohen karzinomrisiko behaftet
32. Representation of elderly persons and women in published randomized trials of acute coronary syndromes
33. 506 Q mutation in a random population sample - Associations with cardiovascular risk factors and coagulation variables
34. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers
35. Nitric oxide stimulatory and endothelial protective effects of idoxifene, a selective estrogen receptor modulator, in the splanchnic artery of the ovariectomized rat
36. Bad blood by mutation
37. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs
38. Cause of in-hospital death in 12232 consecutive patients undergoing percutaneous transluminal coronary angioplasty
39. Atrial fibrillation: Are there gender differences?
40. Tamoxifen and trisk of idiopathic venous thromboembolism
41. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid
42. Hormone replacement therapy and cardiovascular diesease: A statement for healthcare professionals from the American Heart Association
43. Design and methods of the Raloxifene Use for The Heart (RUTH) study
44. The Besancon Stroke Registry: An acute stroke registry of 2.500 consecutive patients
45. Assessment of the risk for venous thromboembolism among users of hormone replacement therapy
46. Oral contraception and fatal pulmonary embolism
47. Menopausal status and risk factors for cardiovascular disease
48. World distribution of factor V Leiden
49. Mutation in the gene coding for coagulation factor V and the risk of myocardial in farction, stroke, and venous thrombosis in apparently healthy men
50. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
51. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
52. Cardiovascular disease in postmenopausal women
53. Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause
54. Sex difference in antithrombotic effect of aspirin
55. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year nurses' health study
56. Incidence of acute pulmonary embolism in a general hospital: Relation to age, sex and race
57. Chest pain in women: Clinical, investigative, and prognostic features
58. Changes in risk factors and the decline in mortality from cardiovascular disease - The Framingham Heart Study
59. Comparative diagnostic value of dobutamine stress echocardiography and stress thallium-201 single-photon-emission computed tomography for detecting coronary artery disease in women
60. Geschlechtsspezifische entwicklung der frau und ihre störungen
61. Sex differences in cardiovascular disease: Are women with low socioeconomic status at high risk?
62. Thrombophilie und antithrombotische prävention in gynäkologie und geburtshilfe
63. Stroke and gender
64. Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: A community-wide perspective